Overview
- Regulatory Toxicology and Pharmacology retracted the review after finding undisclosed Monsanto involvement, possible payments to authors, and conclusions based solely on unpublished company studies.
- The retraction followed a formal complaint by researchers Alexander Kaurov and Naomi Oreskes, who analyzed the paper’s impact and requested action.
- The review was widely cited in scientific and policy documents, including Health Canada’s 2017 re‑evaluation of glyphosate.
- Health Canada says the retraction does not alter its approval, emphasizing its broader assessment of primary data and extensive literature.
- Bayer defends the safety of glyphosate products and says Monsanto’s contributions were acknowledged, while Canadian environmental groups urge a moratorium and a fast‑tracked special review.